-
Views
-
Cite
Cite
M.A. Thomson, D.G. Stewart, H.M. Lewis, Chronic actinic dermatitis treated with mycophenolate mofetil, British Journal of Dermatology, Volume 152, Issue 4, 1 April 2005, Pages 784–786, https://doi.org/10.1111/j.1365-2133.2005.06445.x
Close - Share Icon Share
Summary
Chronic actinic dermatitis (CAD) is a persistent photodermatosis that usually affects elderly men. We report two male patients, aged 55 years (patient A) and 49 years (patient B), who presented with an eczematous eruption on sun‐exposed skin. Phototesting revealed a markedly reduced 24‐h minimal erythema dose (MED). Both patients had refractory disease and developed significant side‐effects to conventional therapies, including topical steroids, prednisolone, psoralen with ultraviolet A, azathioprine and ciclosporin. They had each received at least 6 years of treatment prior to commencing mycophenolate mofetil (MMF). Each noted a significant improvement in symptoms within 6 weeks and subsequent clearing of the eczematous lesions. Patient A still requires continuous treatment with MMF 500 mg twice daily to prevent relapses. Patient B maintains remission by using MMF 1 g twice daily only during the spring and summer months. Both patients have tolerated the treatment well with no abnormalities in blood cell counts or liver biochemistry. Since commencing MMF, their quality of life has significantly improved. These observations suggests that MMF should be considered as an alternative treatment to conventional therapies for refractory CAD.
